Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 4.51% and Operating profit at -2.19% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 2.68% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 4.51% and Operating profit at -2.19% over the last 5 years
3
With a fall in EPS of -235.85%, the company declared Very Negative results in Mar 26
4
With ROE of 1.70%, it has a very expensive valuation with a 1.88 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,238 Million (Small Cap)
116.00
NA
0.47%
0.31
1.70%
2.00
Revenue and Profits:
Net Sales:
535 Million
(Quarterly Results - Jun 2026)
Net Profit:
-14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.28%
0%
7.28%
6 Months
-0.65%
0%
-0.65%
1 Year
-8.96%
0%
-8.96%
2 Years
12.84%
0%
12.84%
3 Years
-23.45%
0%
-23.45%
4 Years
-24.71%
0%
-24.71%
5 Years
-42.08%
0%
-42.08%
Beijing Centergate Technologies (Holding) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.51%
EBIT Growth (5y)
-2.19%
EBIT to Interest (avg)
1.59
Debt to EBITDA (avg)
2.00
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
1.08
Tax Ratio
65.21%
Dividend Payout Ratio
31.45%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.60%
ROE (avg)
2.68%
Valuation key factors
Factor
Value
P/E Ratio
116
Industry P/E
Price to Book Value
1.97
EV to EBIT
30.49
EV to EBITDA
13.35
EV to Capital Employed
1.74
EV to Sales
1.61
PEG Ratio
NA
Dividend Yield
0.47%
ROCE (Latest)
5.72%
ROE (Latest)
1.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
535.10
472.40
13.27%
Operating Profit (PBDIT) excl Other Income
51.20
54.50
-6.06%
Interest
15.10
14.70
2.72%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.30
-15.30
6.54%
Operating Profit Margin (Excl OI)
12.60%
21.40%
-0.88%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 13.27% vs -15.72% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 6.54% vs -7,750.00% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,421.20
2,497.60
-3.06%
Operating Profit (PBDIT) excl Other Income
340.40
394.60
-13.74%
Interest
52.00
57.40
-9.41%
Exceptional Items
3.00
8.80
-65.91%
Consolidate Net Profit
61.40
76.40
-19.63%
Operating Profit Margin (Excl OI)
60.30%
59.50%
0.08%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -3.06% vs 10.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -19.63% vs 17.00% in Dec 2024
About Beijing Centergate Technologies (Holding) Co., Ltd. 
Beijing Centergate Technologies (Holding) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






